The past, present, and future of anti-idiotype antibodies

William J Murphy1, Craig P Collins1, Heinz Kohler2

  • 1Departments of Dermatology and Internal Medicine, Hematology/Oncology, University of California (UC) Davis School of Medicine, Sacramento, CA, United States.

Frontiers in Immunology
|December 3, 2025
PubMed

Seminal discoveries led to the concept of the immune system as a complex network of antibodies and B-cells. In 1963, Kunkel et al. described individual antigenic specificities using antibodies directed against antibodies, hinting at the possibility of a network structure in the immune repertoire. In 1973, Jerne proposed the Network Theory that the immune system is a functional network of antibodies (idiotypes) and anti-idiotypic antibodies that are made in response due to the inherent immunogenicity of immunoglobulin variable chains. In 1974, anti-idiotypic responses were observed, providing proof of the Network Theory. In this review, the origin, as well as rise and fall, of idiotype research over the years is traced, citing examples of work that expanded the understanding of the network concept and its potential application. This includes broadly binding anti-idiotypic antibodies, anti-idiotype vaccines, anti-idiotypic antibodies as tools to trace monoclonal antibodies, and as immunotherapeutic biologicals. Future utility from using the Network Theory could involve cocktails of different monoclonal anti-idiotypic monoclonals. Studies can focus on how the Network Theory involves the generation of potential "antigen mirror" effects and how the network ultimately regulates both B and T cell responses over time. Despite the decline in popularity, aspects of the Network Theory are reemerging as evidence is generated on potential roles during host responses to pathogens or vaccines.

Related Concept Videos

Antibody Structure01:10

Antibody Structure

Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.2K
Blood Typing01:10

Blood Typing

Understanding an individual's blood group is a critical component of transfusion medicine. It ensures compatibility in blood transfusions, organ transplants, and even during pregnancy. Determining these blood groups involves the ABO and Rh blood typing systems, utilizing specific antigens and corresponding anti-sera to identify an individual's blood type.
Antigens are protein molecules that reside on the surface of red blood cells (RBCs). The ABO and Rh blood typing systems target...
2.3K
Antibody Structure and Classes01:25

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.
8.1K
Antibody Actions01:26

Antibody Actions

Antibodies, or immunoglobulins, are critical players in the immune system's arsenal against invading pathogens. Produced by B cells and plasma cells, their primary role is to detect and bind to specific antigens, molecules found on the surface of pathogens like bacteria or viruses. Beyond antigen recognition, antibodies perform several vital functions that contribute to immune defense.
Neutralization
Antibodies can bind to pathogens, preventing them from infecting host cells. This process...
2.3K
Hybridoma Technology01:31

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
17.1K
Affinity and Avidity01:41

Affinity and Avidity

Overview
38.4K